SCHEMBL19448786

SCHEMBL19448786

CCC(C)(C)C(=O)N(Cc1ccc(F)c(F)c1)OC

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 19/20 0.69
▸ KDM4E B2RXH2 1/20 0.39
▸ MITF O75030 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19448789 0.86 RIPK1 (0.68) RIPK1
SCHEMBL19448784 0.85 RIPK1 (0.67) RIPK1KDM4E
SCHEMBL17882186 0.84 RIPK1 (0.51) RIPK1KDM4EMITFALDH1A1HTT
SCHEMBL19448787 0.83 RIPK1 (0.50) RIPK1
SCHEMBL17882383 0.82 RIPK1 (0.74) RIPK1
SCHEMBL29638048 0.82 RIPK1 (1.00) RIPK1
SCHEMBL17882205 0.82 RIPK1 (1.00) RIPK1
SCHEMBL17882385 0.79 RIPK1 (0.65) RIPK1ALDH1A1HTT
SCHEMBL19448785 0.77 RIPK1 (0.70) RIPK1KDM4EALDH1A1
SCHEMBL17882371 0.75 RIPK1 (0.56) RIPK1KDM4EMITFALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US disclosed
US-10682319-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-16 — — US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10682319-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885KDM4E 3910/4885MITF 4514/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL RIPK1 2/4885KDM4E 1232/4885MITF 4128/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL RIPK1 2/4885KDM4E 1232/4885MITF 4128/4885
US-20170290790-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885KDM4E 3458/4885MITF 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback